Want to join the conversation?
$ABT's R&D expenses increased by 23.7% in 3Q15, due primarily to higher spending across its various businesses and the impact of higher restructuring costs recorded in the quarter. SG&A expenses for 3Q15 increased 4.5%, due primarily to the impact of the acquisition of CFR Pharmaceuticals in 3Q14 and Veropharm in 4Q14.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.